Disease relevance of (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(2-azoniabicyclo[4.3.0]nona-2,4,10-trien-2-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• Pharmacokinetics and antibacterial efficacy of cefpirome (HR 810) in experimental Escherichia coli and Haemophilus influenzae type b meningitis [1].
• Cefotaxime penetrated only moderately into the cerebrospinal fluid of rabbits with meningitis, whereas cefpimizole, BMY 28142, and HR 810 all exhibited unusually good penetration [2].
• Distribution of cefpirome (HR 810) to exudate in the croton oil-induced rat granuloma pouch and its therapeutic effects on experimental infections in the pouch [3].
• Cefpiramide (HR-810), ceftazidime, piperacillin, ticarcillin, and aztreonam were tested against tobramycin-sensitive and -resistant strains of Pseudomonas aeruginosa and tobramycin/amikacin-resistant isolates of Ps. cepacia recovered from the sputum of patients with cystic fibrosis [4].
• Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients [5].

High impact information on (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(2-azoniabicyclo[4.3.0]nona-2,4,10-trien-2-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum [6].
• High-pressure liquid chromatographic assay and pharmacokinetics of HR 810 after intramuscular injection in rabbits [7].
• In vitro activity of HR 810, a new cephalosporin [8].
• In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients [9].
• The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides [10].

Chemical compound and disease context of (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(2-azoniabicyclo[4.3.0]nona-2,4,10-trien-2-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa [11].
• Against Pseudomonas aeruginosa, HR 810 was as active as cefoperazone, an antipseudomonal agent [12].

Biological context of (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(2-azoniabicyclo[4.3.0]nona-2,4,10-trien-2-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• HR 810 is very stable against hydrolysis by plasmid-coded and chromosomally coded beta-lactamases [10].
• Structure-activity relationships in the cefpirome (HR 810) series: synthesis and antibacterial activity of 7 alpha-methoxy and 7 alpha-formylamino analogues of HR 810 [13].

Analytical, diagnostic and therapeutic context of (6R,7R)-7-[[(2E)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-(2-azoniabicyclo[4.3.0]nona-2,4,10-trien-2-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• Microanalytical high-performance liquid chromatography assay for cefpirome (HR 810) in serum [14].
• After intravenous injection of a single dose of 2.0 g cefpirome (HR 810) and multiple doses of 2.0 g b.i.d. (11 doses) to 10 healthy male volunteers in an open design, concentrations of unchanged drug were measured at various times in serum and urine over 24 and 96 h, respectively [15].

References